Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.36 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26806753 | 0.90 | TSHR (0.41) | POLBKDM1AMAPTPIK3C2BPIK3C2G | |
| SCHEMBL26806777 | 0.89 | TDP1 (0.40) | POLBMAPTPIK3C2BPIK3C2GKDM4E | |
| SCHEMBL29567003 | 0.89 | SMN1; SMN2 (0.36) | POLBKDM1AMAPTPIK3C2BPIK3C2G | |
| SCHEMBL24309272 | 0.89 | SMN1; SMN2 (0.36) | POLBKDM1AMAPTPIK3C2BPIK3C2G | |
| SCHEMBL26806758 | 0.88 | MEN1 (0.39) | POLBKDM1AMAPTPIK3C2BPIK3C2G | |
| SCHEMBL26806726 | 0.87 | POLB (0.43) | POLBMAPTPIK3C2BPIK3C2GTSHR | |
| SCHEMBL26806731 | 0.87 | SCN9A (0.41) | — | |
| SCHEMBL26806775 | 0.87 | BRD4 (0.42) | POLBMAPTPIK3C2BPIK3C2GHTR1A | |
| SCHEMBL26806771 | 0.87 | PGR (0.41) | POLBKDM1AMAPTPIK3C2BPIK3C2G | |
| SCHEMBL26806784 | 0.86 | POLB (0.41) | POLBMAPTPIK3C2BPIK3C2GKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | POLB 3593/4885KDM1A 4709/4885MAPT 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.